Drugmaker Merck has been pushing to new highs, and now it’s pulled back.
The first pattern on today’s chart is a pair of gaps. On February 1, earnings and revenue beat estimates. The second jump on March 27 followed approval of a lung-disease drug. Both of those gaps pushed the stock to record highs.
Next, MRK held last year’s previous all-time high in...
This is my favorite set up that I found this weekend. The chart looks clean on both the weekly and the daily. The trend is slowing while stronger bear bars appear. This could set up into a nice 1R play but, has the juice to move much further IMO.
Abstract:
We perform a comprehensive technical analysis of Merck & Co., Inc. (NYSE: MRK) by dissecting its latest price movements, chart patterns, and technical indicators. This analysis is aimed at shedding light on the potential future price trajectory for MRK, integrating both traditional technical analysis tools and advanced indicators to inform speculative...
Cool looking pattern.
ATH so no price action resistance or moving average resistance
Bear candle gapping into bear candle + inside day candle = have to try
Merck & Co., ( NYSE:MRK ) has achieved a significant milestone in the realm of medical innovation with the recent approval of its groundbreaking treatment for a rare and life-threatening form of high blood pressure. The approval of the drug, known as sotatercept and to be marketed as Winrevair in the US, by the Food and Drug Administration (FDA) marks a pivotal...
Right now, the trend for NYSE:MRK looks positive, meaning it's going up, so it's a good time to take advantage of that momentum. The current value zone, where it's reasonably priced, is between $119 and $124. It's suggested to set a stop loss at $116, meaning if the stock drops below that, it's a signal to sell to limit potential losses. NYSE:MRK is currently...
Merck & Co. (MRK) - signs of potential breakout 4-hour
Merck is a large pharmaceutical company that develops and sells vaccines, including a vaccine for pneumonia. The company's stock is undervalued, and it is starting to show signs of a breakout. The stock is up over 8% in the past month, and it is trading above its 50-day moving average.
Merck & Co....
Analyzing the financial metrics and market dynamics of Bristol-Myers Squibb (BMY) and Merck & Co., Inc. (MRK) provides valuable insights for investors considering adjustments to their investment portfolios.
Reasons to Consider Buying BMY Over MRK:
P/E Ratio: BMY's P/E ratio of 12.93 is substantially lower than MRK's P/E of 966.64, suggesting that BMY is...
This draws a Trailing Stop Line that is n % off the highs - default is 6%. Once the line is hit, it draws an arrow & changes the line yellow. This is useful to see where a broker placed Trailing Stop trade will stop out, when the order is placed using a specified % drawdown in price. It can also be used to see what may be an optimum % to use for a given symbol....
Merck & Co ( NYSE:MRK ) has emerged victorious in its fourth-quarter performance, exceeding market expectations fueled by the remarkable success of its flagship cancer immunotherapy drug, Keytruda. The pharmaceutical giant reported robust financials, driven by a 21% surge in Keytruda sales, catapulting it to the status of the world's best-selling prescription...
Navigating the Oncology Frontier with Harpoon Therapeutics Acquisition
In a significant strategic move, pharmaceutical giant Merck & Co. ( NYSE:MRK ) has announced its plans to acquire cancer drugmaker Harpoon Therapeutics Inc. ( NASDAQ:HARP ) in a transformative deal valued at $680 million. The move aims to solidify Merck's leadership position in the highly...
NYSE:MRK has shown a strong breakout. We see a steady secondary downtrend from May 2023 to early December. Anchoring a VWAP to the May 202 high and another to the October low give us a clear indication of support and resistance. I missed the breakout and retest in early December, as well as the break above the VWAP from the prior high.
Taking a fib retrace from...
NYSE:MRK is heading for a stronger upside after it broke out of the 6-month corrective downside channel. Furthermore, Ichimoku displayed a bullish signal. Near-term price target is at 111.96
Hi, according to my analysis of mrk stock. The stock looks negative. The stock broke the bottom at the 106 level. It also broke the ascending channel to the upside, as shown in the analysis. These are all indications that the stock is still under pressure from sellers. good luck for everbody
